Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Voyager Therapeutics (VYGR) has provided an update.
Voyager Therapeutics’ CFO, Peter P. Pfreundschuh, has agreed to a transition and separation plan, stepping down from his role and all related positions by May 5, 2024. He will remain as Senior Financial Advisor during this transition, continuing to earn his current salary and benefits. Afterward, he’ll provide consulting services until at least June 28, 2024, with the potential for extension. His stock awards will vest during this consulting period, and he’ll have six months post-consultancy to exercise vested options. Concurrently, Robin Swartz has been appointed as the new principal financial and accounting officer, bringing her extensive experience from Genzyme and Sanofi to the role.
See more data about VYGR stock on TipRanks’ Stock Analysis page.
